Immunotherapy: A Potential Approach to Targeting Cancer Stem Cells.


Journal

Current cancer drug targets
ISSN: 1873-5576
Titre abrégé: Curr Cancer Drug Targets
Pays: Netherlands
ID NLM: 101094211

Informations de publication

Date de publication:
2021
Historique:
received: 31 01 2020
revised: 14 03 2020
accepted: 04 04 2020
pubmed: 5 5 2020
medline: 15 12 2021
entrez: 5 5 2020
Statut: ppublish

Résumé

Tumor recurrence and drug resistance are two of the key factors affecting the prognosis of cancer patients. Cancer stem cells (CSCs) are a group of cells with infinite proliferation potential which are not sensitive to traditional therapies, including radio- and chemotherapy. These CSCs are considered to be central to tumor recurrence and the development of drug resistance. In addition, CSCs are important targets in cancer immunotherapy because of their expression of novel tumorassociated antigens, which result from mutations in cancer cells over the course of treatment. Emerging immunotherapies, including cancer vaccines, checkpoint blockade therapies, and transferred immune cell therapies, have all been shown to be more effective when they selectively target CSCs. Such therapies may also provide novel additions to the current therapeutic milieu and may offer new therapeutic combinations for treatment. This review summarizes the relationships between various immunotherapies and CSCs and provides novel insights into potential therapeutic applications for these approaches in the future.

Identifiants

pubmed: 32364076
pii: CCDT-EPUB-106333
doi: 10.2174/1568009620666200504111914
doi:

Substances chimiques

Cancer Vaccines 0
Immune Checkpoint Inhibitors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

117-131

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Wenjun Wang (W)

Cancer Center, The First Hospital of Jilin University, Changchun 130021, Jilin, China.

Ling Bai (L)

Cancer Center, The First Hospital of Jilin University, Changchun 130021, Jilin, China.

Dongsheng Xu (D)

Cancer Center, The First Hospital of Jilin University, Changchun 130021, Jilin, China.

Wei Li (W)

Cancer Center, The First Hospital of Jilin University, Changchun 130021, Jilin, China.

Jiuwei Cui (J)

Cancer Center, The First Hospital of Jilin University, Changchun 130021, Jilin, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH